In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate

OBJECTIVE(S): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time...

Descripción completa

Detalles Bibliográficos
Autores principales: Adyani, Seyed Masih, Rashidzadeh, Hamid, Behdani, Mahdi, Tabatabaei Rezaei, Seyed Jamal, Ramazani, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742571/
https://www.ncbi.nlm.nih.gov/pubmed/36544521
http://dx.doi.org/10.22038/IJBMS.2022.67038.14701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742571/
https://www.ncbi.nlm.nih.gov/pubmed/36544521
http://dx.doi.org/10.22038/IJBMS.2022.67038.14701

Ejemplares similares